The recognized global leader in neuromodulation devices to treat blindness, the company leverages its 20 years of technology innovation to develop devices to treat the broadest population of sight-impaired individuals. Inspired by personal connections with a retinitis pigmentosa diagnosis, Second Sight has researched, designed and created the world’s first FDA and CE Mark approved device for providing artificial vision in people with late-stage RP.
The company is actively developing a cortical stimulation device that bypasses the diseased eye and has the potential to provide a new form of vision to individuals blinded due to a wide range of causes.
– See more at: http://www.secondsight.com
